FindTrial
Sign In

A study on the impact of genetic polymorphism in Chinese CML patients on imatinib therapeutic effect.

A study on the impact of genetic polymorphism in Chinese CML patients on imatinib therapeutic effect.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012313
Enrollment
Unknown
Registered
2017-08-09
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukemia

Interventions

All people:N/A

Sponsors

Hebei Yanda Ludaopei Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as Ph+ and/or BCR-ABL1+ chronic phase CML; 2. Male or female and 18 years of age or older; 3. Have been taken imatinib once daily for more than one week regularly in time and dose; 4. Completed the questionnaire survey; 5. Signed the patient authorization form.

Exclusion criteria

Exclusion criteria: 1. Accomplaned with atrial fibrillation; 2. Accomplaned with Symptomatic heart failure or severe arrhythmia; 3. Accomplaned with deep venous thrombosis; 4. Accomplaned with any other kind of Malignance; 5. Severe infection; 6. Undergoing antituberculosis therapy; 7. Severe liver failure; 8. Severe renal failure; 9. pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Plasma imatinib rough concentration;Intracellular concentration;Genotypes of CYP3A4 and CYP3A5;Genotypes of transport proteins and its expression;BCL2L11 genotypes;—

Countries

China

Contacts

Public ContactHongxing Liu

Hebei Yanda Ludaopei Hospital

lhongxing@gmail.com+86 13693165205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026